These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 27309616)
21. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Morency E; Leitao MM; Soslow RA Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225 [TBL] [Abstract][Full Text] [Related]
22. Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4. Lassus H; Laitinen MP; Anttonen M; Heikinheimo M; Aaltonen LA; Ritvos O; Butzow R Lab Invest; 2001 Apr; 81(4):517-26. PubMed ID: 11304571 [TBL] [Abstract][Full Text] [Related]
23. EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas. Gao W; Zhang Q; Wang Y; Wang J; Zhang S APMIS; 2017 Feb; 125(2):122-127. PubMed ID: 28120491 [TBL] [Abstract][Full Text] [Related]
24. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related]
25. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457 [TBL] [Abstract][Full Text] [Related]
26. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388 [TBL] [Abstract][Full Text] [Related]
27. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors. Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384 [TBL] [Abstract][Full Text] [Related]
28. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008 [TBL] [Abstract][Full Text] [Related]
29. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711 [TBL] [Abstract][Full Text] [Related]
30. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Yoshida A; Sarian LO; Andrade LA; Pignataro F; Pinto GA; Derchain SF Int J Gynecol Cancer; 2007; 17(3):607-14. PubMed ID: 17504375 [TBL] [Abstract][Full Text] [Related]
31. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma]. Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343 [TBL] [Abstract][Full Text] [Related]
32. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402 [TBL] [Abstract][Full Text] [Related]
33. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective. Hashmi AA; Hussain ZF; Bhagwani AR; Edhi MM; Faridi N; Hussain SD; Khan M BMC Res Notes; 2016 Apr; 9():205. PubMed ID: 27052022 [TBL] [Abstract][Full Text] [Related]
35. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D; Hirschmann A; Löhrs U; Diebold J Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438 [TBL] [Abstract][Full Text] [Related]
36. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Ross JS; Yang F; Kallakury BV; Sheehan CE; Ambros RA; Muraca PJ Am J Clin Pathol; 1999 Mar; 111(3):311-6. PubMed ID: 10078105 [TBL] [Abstract][Full Text] [Related]
37. HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization. Heinrich JK; Böttcher-Luiz F; Andrade LL; Davidson S; Bonds L; Stephens J; Varella-Garcia M Int J Gynecol Cancer; 2004; 14(6):1078-85. PubMed ID: 15571613 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478 [TBL] [Abstract][Full Text] [Related]
39. HER2 expression in ovarian mucinous carcinomas in Tunisia. Missaoui N; Abdelkarim SB; Ayachi M; Hmissa S; Yaacoubi MT Asian Pac J Cancer Prev; 2014; 15(19):8121-5. PubMed ID: 25338994 [TBL] [Abstract][Full Text] [Related]
40. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]